



Precision BioSciences to Attend and Present at Upcoming September Investor Conferences

September 6, 2023 at 7:00 AM EDT

DURHAM, N.C.--(BUSINESS WIRE)--Sep. 6, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), a gene editing company utilizing its proprietary ARCUS® platform to develop *in vivo* gene editing therapies, today announced that members of management will participate in the following investor conferences in the month of September:

H.C. Wainwright Annual Global Investment Conference 2023

Date: September 11, 2023

Time: Available on-demand at 7:00 am ET

Jefferies Gene Editing/Gene Therapy Summit

Date: September 27, 2023

Time: 8:30 am ET

Live webcasts will be accessible on Precision's website in the Investors section under Events & Presentations at <https://investor.precisionbiosciences.com/events-and-presentations>. An archived replay will be available for approximately 30 days following the event.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of *in vivo* gene editing candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20230906587845/en/): <https://www.businesswire.com/news/home/20230906587845/en/>

Mei Burris

Director, Investor Relations and Finance

Mei.Burris@precisionbiosciences.com

Source: Precision BioSciences, Inc.